Acute application of dorzolamide increases retinal and epipapillary optic nervehead circulation in healthy subjects

O. Arend, Alon Harris, B. J. Martin

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose. Dorzolamide is the first carbonic anhydrase inhibitor (CAI) for the treatment of glaucoma. In addition to the established hypotensive effects, CAI agents have also been reported to have some vasuactive effects. The ocular hemodynamic effects of Dorzolamide had yet to be investigated. This study investigated the effects on retinal and epipapillary circulation following acute application. Methods. In a double-masked placebo-controlled cross-over design, intraocular pressure (IOP) and scanning laser video fluorescein angiography were evaluated in 13 normal subjects at baseline and 2 hours following application. Results. The drug hastened arteriovenous passage time (p<0.05; 18%) and accelerated capillary blood velocities in the macula (p<0.05; 16%) and the superficial optic nervehead (p<0.05; 15%) while remaining arterial and venous diameters unaffected. The placebo failed to alter these measures. IOP also decreased significantly from 15.7 ±0.7 to 13.7 ±0.7 mmHg (p<0.01; 22%) after the acute application. Conclusion. Dorzolamide caused an acute significant increase in retinal and superficial optic nervehead circulation. These results suggests that Dorzolamide could benefit patients with ocular vascular illness characterized by vascular insufficiency.

Original languageEnglish
JournalInvestigative Ophthalmology and Visual Science
Volume37
Issue number3
StatePublished - Feb 15 1996

Fingerprint

dorzolamide
Healthy Volunteers
Carbonic Anhydrase Inhibitors
Intraocular Pressure
Blood Vessels
Placebos
Fluorescein Angiography
Glaucoma
Cross-Over Studies
Lasers
Hemodynamics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Ophthalmology

Cite this

@article{66e29369037245d6a4458be606f292a9,
title = "Acute application of dorzolamide increases retinal and epipapillary optic nervehead circulation in healthy subjects",
abstract = "Purpose. Dorzolamide is the first carbonic anhydrase inhibitor (CAI) for the treatment of glaucoma. In addition to the established hypotensive effects, CAI agents have also been reported to have some vasuactive effects. The ocular hemodynamic effects of Dorzolamide had yet to be investigated. This study investigated the effects on retinal and epipapillary circulation following acute application. Methods. In a double-masked placebo-controlled cross-over design, intraocular pressure (IOP) and scanning laser video fluorescein angiography were evaluated in 13 normal subjects at baseline and 2 hours following application. Results. The drug hastened arteriovenous passage time (p<0.05; 18{\%}) and accelerated capillary blood velocities in the macula (p<0.05; 16{\%}) and the superficial optic nervehead (p<0.05; 15{\%}) while remaining arterial and venous diameters unaffected. The placebo failed to alter these measures. IOP also decreased significantly from 15.7 ±0.7 to 13.7 ±0.7 mmHg (p<0.01; 22{\%}) after the acute application. Conclusion. Dorzolamide caused an acute significant increase in retinal and superficial optic nervehead circulation. These results suggests that Dorzolamide could benefit patients with ocular vascular illness characterized by vascular insufficiency.",
author = "O. Arend and Alon Harris and Martin, {B. J.}",
year = "1996",
month = "2",
day = "15",
language = "English",
volume = "37",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "3",

}

TY - JOUR

T1 - Acute application of dorzolamide increases retinal and epipapillary optic nervehead circulation in healthy subjects

AU - Arend, O.

AU - Harris, Alon

AU - Martin, B. J.

PY - 1996/2/15

Y1 - 1996/2/15

N2 - Purpose. Dorzolamide is the first carbonic anhydrase inhibitor (CAI) for the treatment of glaucoma. In addition to the established hypotensive effects, CAI agents have also been reported to have some vasuactive effects. The ocular hemodynamic effects of Dorzolamide had yet to be investigated. This study investigated the effects on retinal and epipapillary circulation following acute application. Methods. In a double-masked placebo-controlled cross-over design, intraocular pressure (IOP) and scanning laser video fluorescein angiography were evaluated in 13 normal subjects at baseline and 2 hours following application. Results. The drug hastened arteriovenous passage time (p<0.05; 18%) and accelerated capillary blood velocities in the macula (p<0.05; 16%) and the superficial optic nervehead (p<0.05; 15%) while remaining arterial and venous diameters unaffected. The placebo failed to alter these measures. IOP also decreased significantly from 15.7 ±0.7 to 13.7 ±0.7 mmHg (p<0.01; 22%) after the acute application. Conclusion. Dorzolamide caused an acute significant increase in retinal and superficial optic nervehead circulation. These results suggests that Dorzolamide could benefit patients with ocular vascular illness characterized by vascular insufficiency.

AB - Purpose. Dorzolamide is the first carbonic anhydrase inhibitor (CAI) for the treatment of glaucoma. In addition to the established hypotensive effects, CAI agents have also been reported to have some vasuactive effects. The ocular hemodynamic effects of Dorzolamide had yet to be investigated. This study investigated the effects on retinal and epipapillary circulation following acute application. Methods. In a double-masked placebo-controlled cross-over design, intraocular pressure (IOP) and scanning laser video fluorescein angiography were evaluated in 13 normal subjects at baseline and 2 hours following application. Results. The drug hastened arteriovenous passage time (p<0.05; 18%) and accelerated capillary blood velocities in the macula (p<0.05; 16%) and the superficial optic nervehead (p<0.05; 15%) while remaining arterial and venous diameters unaffected. The placebo failed to alter these measures. IOP also decreased significantly from 15.7 ±0.7 to 13.7 ±0.7 mmHg (p<0.01; 22%) after the acute application. Conclusion. Dorzolamide caused an acute significant increase in retinal and superficial optic nervehead circulation. These results suggests that Dorzolamide could benefit patients with ocular vascular illness characterized by vascular insufficiency.

UR - http://www.scopus.com/inward/record.url?scp=33750157001&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750157001&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750157001

VL - 37

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 3

ER -